|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Moexipril#Use in Specific Populations]] |
| {{Moexipril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ====Nursing Mothers====
| |
| | |
| It is not known whether moexipril hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when moexipril hydrochloride is given to a nursing mother.
| |
| | |
| ====Pediatric Use====
| |
| | |
| Neonates with a history of in utero exposure to moexipril hydrochloride:
| |
| | |
| If [[oliguria]] or [[hypotension]] occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or [[dialysis]] may be required as a means of reversing [[hypotension]] and/or substituting for disordered renal function.
| |
| | |
| Safety and effectiveness of moexipril hydrochloride in pediatric patients have not been established.
| |
| | |
| ====Geriatric Use====
| |
| | |
| Clinical studies of moexipril hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
| |
| | |
| ====Decreased Renal Function====
| |
| | |
| The effective elimination t ½ and AUC of both moexipril and moexiprilat are increased with decreasing renal function. There is insufficient information available to characterize this relationship fully, but at creatinine clearances in the range of 10 to 40 mL/min, the t ½ of moexiprilat is increased by a factor of 3 to 4.
| |
| | |
| ====Decreased Hepatic Function====
| |
| | |
| In patients with mild to moderate [[cirrhosis]] given single 15 mg doses of moexipril, the C max of moexipril was increased by about 50% and the AUC increased by about 120%, while the C max for moexiprilat was decreased by about 50% and the AUC increased by almost 300%.
| |
| | |
| ====Elderly Patients====
| |
| | |
| In elderly male subjects (65 to 80 years old) with clinically normal renal and hepatic function, the AUC and Cmax of moexiprilat is about 30% greater than those of younger subjects (19 to 42 years old).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |